CB
Caravan Biologix develops AI-designed CAR-Directed BioSpheres (Mini-CARs) as allogeneic therapeutic agents that emulate immune cell functions. These miniaturized biospheres offer highly targeted release of apoptotic proteins to treat solid tumors and hereditary diseases with reduced cytotoxicity compared to whole-cell therapies. The platform is available for licensing to develop novel pipelines or enhance existing therapeutic approaches.
Updated 4 months ago
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Caravan Biologix develops AI-designed CAR-Directed BioSpheres (Mini-CARs) as allogeneic therapeutic agents that emulate immune cell functions. These miniaturized biospheres offer highly targeted release of apoptotic proteins to treat solid tumors and hereditary diseases with reduced cytotoxicity compared to whole-cell therapies. The platform is available for licensing to develop novel pipelines or enhance existing therapeutic approaches.